Results 21 to 30 of about 26,095 (135)

Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin

Heart Views, 2023
Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment ...
Monirah Abdulrahman Albabtain, Zaid Dakheel Alanazi, Nawaf Hamoud Al-Mutairi, Ola Alyafi, Raneem Albanyan, Amr A Arafat   +5 more
doaj   +1 more source

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Stroke Research and Treatment, 2021
Introduction. Rivaroxaban is a new anticoagulant providing benefits for the treatment of patients with atrial fibrillation (AF). This study is aimed at evaluating the cost-effectiveness of rivaroxaban compared to warfarin in patients with AF.
Neda Jaberi, Zahra Kavosi, Etrat Hooshmandi, Nasrin Moradi, Khosro Keshavarz, Afshin Borhani-Haghighi   +5 more
doaj   +1 more source

Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

BMC Pharmacology and Toxicology, 2020
Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li, Liping Du, Xiaowan Tang, Yuexin Chen, Dan Mei   +4 more
doaj   +1 more source

Rivaroxaban prescribing in a Saudi tertiary care teaching hospital

Saudi Pharmaceutical Journal, 2018
Purpose: This drug utilization review (DUR) aimed to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physicians’ prescribing practice.
Ahmed Yacoob Mayet, Ahmed Ibrahim Alsaqer, Abdullah Musa Alhammad, Hussain Abdulrahman Al-Omar   +3 more
doaj   +1 more source

Rivaroxaban and Hemostasis in Emergency Care

Emergency Medicine International, 2014
Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Jürgen Koscielny, Edita Rutkauskaite
doaj   +1 more source

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Frontiers in Pharmacology, 2022
Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or ...
Tingting Zhao, Xuening Li, Yanwei Chen, Jie Du, Xiaodong Chen, Dalong Wang, Liyan Wang, Shan Zhao, Changyuan Wang, Changyuan Wang, Qiang Meng, Qiang Meng, Huijun Sun, Huijun Sun, Kexin Liu, Kexin Liu, Jingjing Wu, Jingjing Wu   +17 more
doaj   +1 more source

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Analytical Cellular Pathology, 2020
Background. Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. Objective.
Yan Huang, Linli Duan, Wenjun He, Cheng Hong, Yehui Guo, Xinni Wang, Nuofu Zhang, Yanghang Chen, Tao Wang, Jian Wang, Chunli Liu   +10 more
doaj   +1 more source

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Gastroenterology Research and Practice, 2016
Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes, Subbaramiah Sridhar   +7 more
doaj   +1 more source

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

Frontiers in Pharmacology, 2022
The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr, Andrea Zimmermann, Friedeborg Seitz, Angelika Dienel   +3 more
doaj   +1 more source

Hematoma espontáneo de pared abdominal asociado al uso de anticoagulantes orales de acción directa

Revista Ciencias de la Salud
Introducción: El hematoma espontáneo de la pared abdominal (HEPA) es un evento infrecuente y potencialmente fatal; Se describe  la anticoagulación como el principal factor de riesgo, en especial con el uso de warfarina.
Sandra Brigitte Amado Garzon, Paula Andrea Ruiz Talero, Maria Natalia Serrano   +2 more
doaj   +1 more source